IL315411A - Pure forms of crystalline eticarpant - Google Patents
Pure forms of crystalline eticarpantInfo
- Publication number
- IL315411A IL315411A IL315411A IL31541124A IL315411A IL 315411 A IL315411 A IL 315411A IL 315411 A IL315411 A IL 315411A IL 31541124 A IL31541124 A IL 31541124A IL 315411 A IL315411 A IL 315411A
- Authority
- IL
- Israel
- Prior art keywords
- aticaprant
- crystalline
- pure forms
- pure
- forms
- Prior art date
Links
- ZHPMYDSXGRRERG-DEOSSOPVSA-N aticaprant Chemical compound CC1=CC(C)=CC([C@H]2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-DEOSSOPVSA-N 0.000 title 1
- 229940121408 aticaprant Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315411A true IL315411A (en) | 2024-11-01 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315411A IL315411A (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline eticarpant |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (https=) |
| EP (1) | EP4489748A1 (https=) |
| JP (1) | JP2025508071A (https=) |
| KR (1) | KR20240158951A (https=) |
| CN (1) | CN119156210A (https=) |
| AU (1) | AU2023231493A1 (https=) |
| CA (1) | CA3254503A1 (https=) |
| CL (1) | CL2024002643A1 (https=) |
| CO (1) | CO2024012457A2 (https=) |
| IL (1) | IL315411A (https=) |
| JO (1) | JOP20240195A1 (https=) |
| MX (1) | MX2024010978A (https=) |
| PE (1) | PE20242109A1 (https=) |
| TW (1) | TW202345795A (https=) |
| WO (1) | WO2023170547A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) * | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| PH12023552963A1 (en) * | 2021-05-04 | 2024-03-11 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
-
2023
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240158951A (ko) | 2024-11-05 |
| EP4489748A1 (en) | 2025-01-15 |
| JOP20240195A1 (ar) | 2024-09-05 |
| JP2025508071A (ja) | 2025-03-21 |
| CL2024002643A1 (es) | 2025-01-24 |
| AU2023231493A1 (en) | 2024-10-24 |
| TW202345795A (zh) | 2023-12-01 |
| US20250326714A1 (en) | 2025-10-23 |
| WO2023170547A1 (en) | 2023-09-14 |
| MX2024010978A (es) | 2024-12-06 |
| CN119156210A (zh) | 2024-12-17 |
| CO2024012457A2 (es) | 2024-09-30 |
| PE20242109A1 (es) | 2024-10-28 |
| CA3254503A1 (en) | 2023-09-14 |
| US20230348377A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL316075A (en) | Crystalline form of lenifranor | |
| IL315411A (en) | Pure forms of crystalline eticarpant | |
| GB202204778D0 (en) | Novel crystalline salt forms of mesembrine | |
| GB202102360D0 (en) | Crystalline compound | |
| AU2024314489A1 (en) | Crystalline salts of linsitinib | |
| IL289214A (en) | Crystalline forms of plasma kallikrein inhibitors | |
| IL321171A (en) | Crystalline forms of 2-oxoquinazoline | |
| IL299031A (en) | Production of pharmaceutical pure crystals | |
| IL325727A (en) | Crystalline form | |
| LT4615820T (lt) | Kristalinės evenamido formos | |
| HK40121423A (en) | Pure forms of crystalline aticaprant | |
| GB202009218D0 (en) | Crystalline forms of entrectinib | |
| GB202002054D0 (en) | Crystalline forms of entrectinib | |
| GB202014196D0 (en) | Crystalline form III of tetraacetylethylenediamine | |
| EP4121434A4 (en) | CRYSTALLINE FORMS OF SQUALAMINE | |
| CA3288524A1 (en) | Crystalline forms of evenamide | |
| HK40111295A (en) | Crystalline forms of trofinetide | |
| HK40116601A (en) | Crystalline form of lanifibranor | |
| HK40096047A (en) | Crystalline form of aspacytarabine | |
| HK40082031A (en) | Crystalline form of lnp023 | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| CA3269718A1 (en) | Crystalline form of deuruxolitinib | |
| HK40104547A (en) | Crystalline forms of ceftibuten | |
| CA3296181A1 (en) | Crystalline salts of linsitinib | |
| HK40106413A (en) | Crystalline forms of isoxazoline compound |